A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide
LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who
experience progressive disease in the randomized part of the study may proceed to an
open-label extension part with intensified treatment with CAM2029.